Not sure if this have been posted before, apparently it was only published last month, so maybe hasn't been posted yet.
The results of the study seem positive. IMO, LDX have a product which can be a significant contributor to the global fight against microbial resistance to antibiotics.
A study on the use of FebriDX: https://bjgpopen.org/content/8/3/BJGPO.2024.0024
Aim: "As part of a larger feasibility study, we explored the views of healthcare professionals (HCPs) and patients on the use of FebriDx to safely reduce antibiotic prescriptions for lower respiratory tract infections (LRTIs) in primary care."
Conclusion: "FebriDx was perceived as a useful tool to guide antibiotic prescribing and support shared decision making. Initial practical problems with testing and communicating results are potential barriers to use. Training and practice on using the test and effective communication are likely to be important elements in ensuring patient understanding and satisfaction, and successful adoption."
Add to My Watchlist
What is My Watchlist?
